The first treatment for West Nile virus. A robotic device for children with cerebral palsy. A universal antivenom for snake bites. These goals emerge from three of the 10 translational research projects receiving funding from the Flinn Foundation in 2022 as part of a program to advance new products and services to improve patient care.Continue reading
Author Archive: AZBio
AlphaLogix announces market release of AlphaFlo® canine allograft
PHOENIX, March 31, 2022 /PRNewswire/ — Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo®. Equus Innovations is also the manufacturer of the highly successful RenoVō® equine allograft, distributed by Equine Amnio Solutions, LLC (EAS).
New ASU center to create a better, more efficient blueprint for tech transfer
Global Center for Technology Transfer will focus on research, education
Flinn awards $5.5M grant to UArizona medical school in Phoenix to support translational research
The University of Arizona College of Medicine-Phoenix will receive $5.5 million over five years from the Flinn Foundation to support translational research in cardiovascular diseases, neurosciences, and serious mental illnesses.Continue reading
BIO Statement on CMS National Coverage Determination for Drugs Used to Treat Patients Suffering from Alzheimer’s Disease
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. In its official statement, the Biotechnology Innovation Organization (BIO) shares why the CMS Decision is an enormous setback for Alzheimer’s patients and a dangerous infringement on FDA’s Scientific Autonomy.
HTG Expands Features of Proprietary HTG EdgeSeq Technology
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample
Phoenix to be Site of New UArizona Health Sciences Center Targeting Immunotherapies
The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine.
Castle Biosciences to Acquire AltheaDx
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental healthContinue reading
Valley Fever Collaborative – Creating Defenses Against Disease
The Valley Fever Collaborative is an initiative that supports a collaborative effort between Arizona’s three state universities focused on the development of precision medicine approaches, drug development and environmental risk abatement to reduce the financial cost and human burden of Valley Fever.
Get Engaged In the SBIR STTR Reauthorization Discussion
The SBIR/STTR Programs are currently set to expire on September 30, 2022. It would be damaging to American innovation and competitiveness if these programs were to expire before a full reauthorization can be passed. The SBIR/STTR Programs enable small businesses to develop and commercialize new innovative technologies and have a proven track record of promoting competition through a merit-based application process. Since their establishment in 1982, these programs have provided over 179,000 awards, totaling more than $54.3 billion, to U.S. small businesses. A study by the National Academy of Sciences found a commercialization rate of 50-60% for SBIR/STTR investments. You can see the impact of SBIR/STTR in Arizona by clicking here.